The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the
effectiveness of antibody therapeutics necessitates development of next-generation …

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and
therapeutic antibodies underscores the urgent need for new antibody-based tools that …

Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 receptor-binding domain (RBD)
showed high efficacy in the prevention and treatment of COVID-19. However, the rapid …

Bispecific antibodies have emerged as a promising strategy for curtailing severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report …

Introduction The emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants has caused unprecedented health and socioeconomic crises, necessitating …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 760 million cases and> …

The emergence of coronavirus disease 2019 (COVID-19) pandemic led to an urgent need to
develop therapeutic interventions. Among them, neutralizing antibodies play crucial roles for …

A current challenge is the emergence of SARS-CoV-2 variants, such as BQ. 1.1 and XBB.
1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) neutralizing antibodies
are shown to be effective therapeutics for providing coronavirus disease 2019 (COVID‐19) …

As the dynamic evolution of SARS-CoV-2 led to reduced efficacy in monoclonal neutralizing
antibodies and emergence of immune escape, the role of bispecific antibodies becomes …